Author(s): Baldomero H, Gratwohl M, Gratwohl A, Tichelli A, Niederwieser D,
Abstract Share this page
Abstract Six hundred and twenty-four centers from 43 countries reported a total of 31,322 hematopoietic SCT (HSCT) to this 2009 European Group for Blood and Marrow Transplantation (EBMT) survey with 28,033 first transplants (41\% allogeneic, 59\% autologous). The main indications were leukemias (31\%; 92\% allogeneic), lymphomas (58\%; 12\% allogeneic), solid tumors (5\%; 6\% allogeneic) and non-malignant disorders (6\%; 88\% allogeneic). There were more unrelated than HLA-identical sibling donors (51 vs 43\%) for allogeneic HSCT; the proportion of peripheral blood as stem cell source was 99\% for autologous and 71\% for allogeneic HSCT. Allogeneic and autologous HSCT continued to increase by about 1000 HSCT per year since 2004. Patterns of increase were distinct and different. In a trend analysis, allogeneic HSCT increased in all World Bank Categories (P=0.01, two sided; all categories), autologous HSCT increased in middle- (P=0.01, two sided) and low-income (P=0.01, two sided) countries. EBMT practice guidelines appeared to have an impact on trend, with a clear increase in absolute numbers within the categories 'standard' and 'clinical option' for both allogeneic and autologous HSCT (P=0.01, two sided; for both allogeneic and autologous HSCT) and a clear decrease in autologous HSCT for the 'developmental' and 'generally not recommended' indications (P=0.01, two sided). These data illustrate the status and trends of HST in Europe.
This article was published in Bone Marrow Transplant
and referenced in Journal of Stem Cell Research & Therapy